Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.~* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2~* Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug~Exclusion Criteria:~* Prior development of disease progression during high-dose dexamethasone containing therapy~* Pregnant or lactating females~* The development of a desquamating rash while taking thalidomide~* Use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment~* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm3~* Laboratory abnormalities: Platelet count \< 75,000/mm3~* Laboratory abnormalities: Serum creatinine \> 2.5 mg/dL~* Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase (SGOT)/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT) \> 3.0 x upper limit of normal~* Laboratory abnormalities: Serum total bilirubin \> 2.0 mg/dL~* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for ≥ 3 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-5013 plus dexamethasone (Type: EXPERIMENTAL): Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
- Dexamethasone plus placebo (Type: EXPERIMENTAL): Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).